[go: up one dir, main page]

NO20030128L - Treatment of B cell malignancy using combination of B cell-reducing antibody and immunomodulatory antibody related applications - Google Patents

Treatment of B cell malignancy using combination of B cell-reducing antibody and immunomodulatory antibody related applications

Info

Publication number
NO20030128L
NO20030128L NO20030128A NO20030128A NO20030128L NO 20030128 L NO20030128 L NO 20030128L NO 20030128 A NO20030128 A NO 20030128A NO 20030128 A NO20030128 A NO 20030128A NO 20030128 L NO20030128 L NO 20030128L
Authority
NO
Norway
Prior art keywords
cell
antibody
treatment
combination
related applications
Prior art date
Application number
NO20030128A
Other languages
Norwegian (no)
Other versions
NO20030128D0 (en
Inventor
Nabil Hanna
Kandasamy Hariharan
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/772,938 external-priority patent/US20020006404A1/en
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of NO20030128D0 publication Critical patent/NO20030128D0/en
Publication of NO20030128L publication Critical patent/NO20030128L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20030128A 2000-07-12 2003-01-10 Treatment of B cell malignancy using combination of B cell-reducing antibody and immunomodulatory antibody related applications NO20030128L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21770600P 2000-07-12 2000-07-12
US09/772,938 US20020006404A1 (en) 1999-11-08 2001-01-31 Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
PCT/US2001/015677 WO2002004021A1 (en) 2000-07-12 2001-05-16 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications

Publications (2)

Publication Number Publication Date
NO20030128D0 NO20030128D0 (en) 2003-01-10
NO20030128L true NO20030128L (en) 2003-03-12

Family

ID=26912176

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030128A NO20030128L (en) 2000-07-12 2003-01-10 Treatment of B cell malignancy using combination of B cell-reducing antibody and immunomodulatory antibody related applications

Country Status (11)

Country Link
EP (1) EP1305045A1 (en)
JP (1) JP2004502742A (en)
KR (2) KR20080039547A (en)
CN (1) CN1446104A (en)
AU (2) AU2001264612C1 (en)
CA (1) CA2415100A1 (en)
IL (1) IL153764A0 (en)
MX (1) MXPA03000306A (en)
NO (1) NO20030128L (en)
SG (1) SG136804A1 (en)
WO (1) WO2002004021A1 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146005A0 (en) 1999-05-07 2002-07-25 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
WO2001097858A2 (en) * 2000-06-20 2001-12-27 Idec Pharmaceuticals Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
MXPA03002262A (en) * 2000-09-18 2003-10-15 Idec Pharma Corp Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination.
ATE391174T1 (en) 2000-10-20 2008-04-15 Chugai Pharmaceutical Co Ltd MODIFIED TPO AGONIST ANTIBODY
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AU2002243718B2 (en) * 2001-01-31 2007-12-06 Biogen Idec Inc. Use of immunoregulatory antibodies in the treatment of neoplastic disorders
AU2002250352C1 (en) * 2001-04-02 2009-04-30 Genentech, Inc. Combination therapy
AU2003210266A1 (en) * 2002-02-14 2003-09-04 Bioinvent International Ab Treatment, diagnosis and imaging of disease
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
CN1729203B (en) 2002-10-17 2014-02-19 根马布股份公司 Anti-CD20 Human Monoclonal Antibody
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
JP2004279086A (en) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc Radiation image conversion panel and method for manufacturing it
EP1609803A4 (en) * 2003-03-31 2006-05-24 Chugai Pharmaceutical Co Ltd MODIFIED ANTIBODY AGAINST CD22 AND ITS USE
BRPI0409534A (en) 2003-04-09 2006-04-18 Genentech Inc methods for treating autoimmune disease and rheumatoid arthritis, method of reducing the risk of negative side effect, use of an antagonist that binds to a b-cell surface marker, and use of an cd20-binding antibody
PT2272868E (en) 2003-06-05 2015-07-07 Genentech Inc Combination therapy for b cell disorders
NZ546173A (en) 2003-10-16 2009-04-30 Micromet Ag Multispecific deimmunized CD3-binders
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
EP1684869B1 (en) * 2003-11-04 2011-07-20 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for b cell-related cancers
DK2380910T3 (en) 2003-11-05 2015-10-19 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
CN102512675A (en) 2004-06-04 2012-06-27 健泰科生物技术公司 Method for treating multiple sclerosis
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
EP2548575A1 (en) * 2005-02-15 2013-01-23 Duke University Anti-CD19 antibodies that mediate ADCC for use in treating autoimmune diseases
EP3623473A1 (en) 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
DK1874821T3 (en) 2005-04-26 2013-07-08 Trion Pharma Gmbh Combination of antibodies with glycocorticoids to treat cancer
US7601335B2 (en) 2005-05-20 2009-10-13 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
KR101360671B1 (en) 2005-06-10 2014-02-07 추가이 세이야쿠 가부시키가이샤 Pharmaceutical compositions containing sc(Fv)2
WO2006132363A1 (en) 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
CN105012953B (en) 2005-07-25 2018-06-22 阿普泰沃研发有限责任公司 B- cells are reduced with CD37- specificity and CD20- specific binding molecules
US20080213273A1 (en) 2005-07-25 2008-09-04 Trubion Pharmaceuticals Inc. Single dose use of CD20-specific binding molecules
ATE497392T1 (en) 2005-08-18 2011-02-15 Genmab As THERAPY WITH ANTI-CD4 ANTIBODIES AND RADIATION
KR20080073725A (en) 2005-11-01 2008-08-11 노파르티스 아게 Use of anti-CD40 antibodies
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
ES2654040T3 (en) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for the purification of bispecific antibodies
EP2019841A2 (en) 2006-04-21 2009-02-04 Novartis AG Antagonist anti-cd40 antibody pharmaceutical compositions
KR101571027B1 (en) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Single chain polyvalent binding protein with effector function
JP5687057B2 (en) 2007-07-09 2015-03-18 ジェネンテック， インコーポレイテッド Prevention of disulfide bond reduction during recombinant production of polypeptides.
US8956611B2 (en) 2007-10-16 2015-02-17 Zymogenetics, Inc. Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
MX340204B (en) 2008-04-11 2016-06-30 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof.
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
MX2012001742A (en) 2009-08-11 2012-03-21 Genentech Inc Production of proteins in glutamine-free cell culture media.
AU2011215900A1 (en) 2010-02-10 2012-07-26 Immunogen, Inc. CD20 antibodies and uses thereof
SG10201501803YA (en) 2010-03-12 2015-05-28 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
AR083847A1 (en) 2010-11-15 2013-03-27 Novartis Ag FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
MA41459A (en) 2015-02-03 2017-12-12 Als Therapy Development Inst ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS
CA3225013A1 (en) 2015-02-24 2016-09-01 Bioatla, Llc Conditionally active proteins
WO2016200676A1 (en) 2015-06-08 2016-12-15 Immunogen, Inc. Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
MY193078A (en) 2015-06-24 2022-09-26 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
CN108699144B (en) 2015-08-28 2022-07-19 德彪发姆国际有限公司 Antibodies and assays for detecting CD37
HK1251480A1 (en) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3 binding polypeptides
RU2753390C1 (en) 2015-10-02 2021-08-13 Ф. Хоффманн-Ля Рош Аг Bispecific antibodies to human cd20/human transferrin receptor and methods for their use
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
WO2017078839A1 (en) 2015-11-02 2017-05-11 Bioatla, Llc Conditionally active polypeptides
KR102784832B1 (en) 2015-12-28 2025-03-21 추가이 세이야쿠 가부시키가이샤 Method for improving the efficiency of purification of Fc region-containing polypeptides
IL297519B2 (en) 2016-04-27 2024-06-01 Abbvie Inc Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
JP2020510608A (en) 2016-11-02 2020-04-09 デビオファーム インターナショナル， エス． アー． Method for improving anti-CD37 immunoconjugate therapy
JP7766392B2 (en) 2017-05-24 2025-11-10 エイエルエス・セラピー・デベロップメント・インスティテュート Therapeutic anti-CD40 ligand antibodies
CN112218662A (en) 2018-05-30 2021-01-12 德彪发姆国际有限公司 anti-CD 37 immunoconjugate dosing regimen
EP4433506A1 (en) 2021-11-16 2024-09-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ATE196606T1 (en) * 1992-11-13 2000-10-15 Idec Pharma Corp THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES DIRECTED AGAINST A DIFFERENTIATION ANTIGEN WHICH EXPRESSION IS RESTRICTED TO HUMAN B LYMPHOCYTES, FOR THE TREATMENT OF B-CELL LYMPHOMA
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof

Also Published As

Publication number Publication date
AU2001264612B2 (en) 2007-02-22
WO2002004021A1 (en) 2002-01-17
CA2415100A1 (en) 2002-01-17
JP2004502742A (en) 2004-01-29
IL153764A0 (en) 2003-07-06
EP1305045A1 (en) 2003-05-02
KR20080039547A (en) 2008-05-07
NO20030128D0 (en) 2003-01-10
WO2002004021A9 (en) 2003-01-16
CN1446104A (en) 2003-10-01
AU2001264612C1 (en) 2007-11-22
MXPA03000306A (en) 2004-04-05
AU6461201A (en) 2002-01-21
SG136804A1 (en) 2007-11-29
AU2001264612B8 (en) 2007-02-22
KR20030031957A (en) 2003-04-23

Similar Documents

Publication Publication Date Title
NO20030128D0 (en) Treatment of B cell malignancy using combination of B cell-reducing antibody and immunomodulatory antibody related applications
DK1604680T3 (en) Use of butulinum toxin in the treatment of neuralgic pain
DK1390389T3 (en) Crypto-blocking antibodies and uses thereof
NO20024874D0 (en) Benzoamide piperidine-containing compounds and related compounds
DE50112013D1 (en) DEODORANTIA AND ANTIPERSPIRANTIES
NO20001446L (en) Methods and devices at submarine production facilities
EP1412378A4 (en) APTAMERES AND ANTIAPTAMERS
DE60017241D1 (en) Underwater treatment arrangement and procedure
DK1370128T3 (en) Combined baler and baler
NO20022334L (en) New composition and application
NO20020781D0 (en) Device and methods of production / injection pipeline
NO20034437D0 (en) Ganglioside-associated recombinant antibodies and their use in the diagnosis and treatment of tumors
NO20030397D0 (en) Amyloid targeting imaging agents and uses of the same
NO983576L (en) Well treatment fluids and methods
DK1216046T3 (en) Hitherto unknown combination of loteprednol and antihistamines
DE60202564D1 (en) Alignment device and magnetization device
DE60220486D1 (en) Switch-back device and switch-back method
NO20024404L (en) Improvements in and regarding corrosion investigation
NO20033854L (en) N-but-3-enyl-norbuprenorphine and methods of use
IS6401A (en) Chemical methods and intermediates
NO20030882D0 (en) Glass ceramic pulp and its use
NO20003555D0 (en) Method of manufacturing structural elements and the resulting elements
NO20001954L (en) Separator Methods and Devices
DE60141890D1 (en) BENDING PROCESS AND BENDING DEVICE
DE60239874D1 (en) COSMETICS AND MAKEUP METHOD

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application